期刊首页 优先出版 当期阅读 过刊浏览 作者中心 关于期刊 English

2021年 第15卷 第1期

摘要

关键词

相关研究

回顶部

《医学前沿（英文）》 >> 2021年 第15卷 第1期 doi: 10.1007/s11684-019-0735-3

Advances on immune-related adverse events associated with immune checkpoint inhibitors

. Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China;.. Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China

收稿日期： 2020-05-05 录用日期： 2020-08-11 发布日期： 2020-08-11
HTML16 PDF 5 收藏 0

下一篇 上一篇

摘要

Immunotherapy has recently led to a paradigm shift in cancer therapy, in which immune checkpoint inhibitors (ICIs) are the most successful agents approved for multiple advanced malignancies. However, given the nature of the non-specific activation of effector T cells, ICIs are remarkably associated with a substantial risk of immune-related adverse events (irAEs) in almost all organs or systems. Up to 90% of patients who received ICIs combination therapy experienced irAEs, of which majority were low-grade toxicity. Cytotoxic lymphocyte antigen-4 and programmed cell death protein-1/programmed cell death ligand 1 inhibitors usually display distinct features of irAEs. In this review, the mechanisms of action of ICIs and how they may cause irAEs are described. Some unsolved challenges, however really engrossing issues, such as the association between irAEs and cancer treatment response, tumor response to irAEs therapy, and ICIs in challenging populations, are comprehensively summarized.

相关研究